First-time generic approvals: fosphenytoin for injection; pantoprazole delayed-release tablets; cefotetan for injection; cefepime for injection.
Fosphenytoin for injection, eq 50 mg/mL phenytoin (equiv to Cerebyx for injection)
ABRAXIS, APOTEX, BAXTER, BEDFORD, HOSPIRA, PHARMAFORCE, TEVA, WOCKHARDT
Pantoprazole delayed-release tablets, eq 20-and 40-mg base (equiv to Protonix delayed-release tablets)
Cefotetan for injection (equiv to Cefotan [discontinued])
ABRAXIS
Cefepime for injection, 500 mg/ vial, 1 g/vial, and 2 g/vial (equiv to Maxipime for injection)
ORCHID
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.